HU230223B1 - Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them - Google Patents

Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them Download PDF

Info

Publication number
HU230223B1
HU230223B1 HU0202704A HUP0202704A HU230223B1 HU 230223 B1 HU230223 B1 HU 230223B1 HU 0202704 A HU0202704 A HU 0202704A HU P0202704 A HUP0202704 A HU P0202704A HU 230223 B1 HU230223 B1 HU 230223B1
Authority
HU
Hungary
Prior art keywords
group
alkyl
short
substituted
optionally
Prior art date
Application number
HU0202704A
Other languages
English (en)
Hungarian (hu)
Inventor
Jacques P Dumas
Teddy Kite Joe
Harold C. E. Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N. Sibley
Ning Su
Stephen James Boyer
Julie A. Dixon
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HUP0202704A2 publication Critical patent/HUP0202704A2/hu
Publication of HUP0202704A3 publication Critical patent/HUP0202704A3/hu
Publication of HU230223B1 publication Critical patent/HU230223B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
HU0202704A 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them HU230223B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
US09/407,600 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (3)

Publication Number Publication Date
HUP0202704A2 HUP0202704A2 (hu) 2002-12-28
HUP0202704A3 HUP0202704A3 (en) 2003-12-29
HU230223B1 true HU230223B1 (en) 2015-10-28

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202704A HU230223B1 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them

Country Status (35)

Country Link
EP (1) EP1228063B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4919567B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100895572B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN100422173C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR025752A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE422494T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU782820B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG65860B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0014382B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2385817C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5200835A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ304767B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60041548D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2000000070A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05258B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2320525T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT200000158A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20020308A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU230223B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL148880A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA25563A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA02003156A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (3) MY143377A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20021520L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ518589A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8503201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20010607A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL205957B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS50369B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2260008C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK287417B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW593315B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA75053C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001023375A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200202760B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523987A (en) * 2000-08-09 2004-10-29 Astrazeneca Ab Indole, azaindole and indazole derivatives having VEGF inhibiting activity
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
PL1603566T3 (pl) * 2003-03-11 2009-07-31 Novartis Ag Zastosowanie pochodnych izochinoliny do leczenia raka i chorób związanych z kinezą MAP
WO2004089412A1 (ja) * 2003-04-08 2004-10-21 Mitsubishi Pharma Corporation 特異的nad(p)hオキシダーゼ抑制剤
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
JP2009533479A (ja) * 2006-04-15 2009-09-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト 肺高血圧症処置用化合物
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
SG11201700855XA (en) 2014-08-28 2017-03-30 Eisai R&D Man Co Ltd High-purity quinoline derivative and method for manufacturing same
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR20250020678A (ko) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
AU2018219637B2 (en) 2017-02-08 2023-07-13 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
EP0722936B1 (en) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000009495A1 (en) * 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
CN1660840A (zh) * 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
DE60110749T2 (de) * 2000-02-09 2006-02-02 Novartis Ag Pyridinderivative als angiogenese- und/oder vegf-rezeptor-tyrosinkinase-inhibitoren

Also Published As

Publication number Publication date
PA8503201A1 (es) 2002-08-26
YU22902A (sh) 2004-12-31
JP4919567B2 (ja) 2012-04-18
PL205957B1 (pl) 2010-06-30
KR100895571B1 (ko) 2009-04-29
MY143377A (en) 2011-05-13
BR0014382B1 (pt) 2014-04-01
HK1091818A1 (zh) 2007-01-26
PE20010607A1 (es) 2001-07-12
WO2001023375A3 (en) 2002-05-02
BRPI0014382B8 (pt) 2021-05-25
KR20080086547A (ko) 2008-09-25
SK5912002A3 (en) 2003-01-09
IL193367A0 (en) 2009-02-11
BG65860B1 (bg) 2010-03-31
AR082232A2 (es) 2012-11-21
CA2385817C (en) 2010-05-04
CN100422173C (zh) 2008-10-01
CN1769283A (zh) 2006-05-10
HK1091819A1 (zh) 2007-01-26
JP2003526632A (ja) 2003-09-09
NZ518589A (en) 2005-03-24
CN100374435C (zh) 2008-03-12
RS50369B (sr) 2009-11-10
UA75053C2 (en) 2006-03-15
MXPA02003156A (es) 2002-09-30
ES2320525T3 (es) 2009-05-25
DE60041548D1 (de) 2009-03-26
IL193367A (en) 2011-03-31
KR20080091505A (ko) 2008-10-13
BR0014382A (pt) 2003-06-24
CO5200835A1 (es) 2002-09-27
SK287417B6 (sk) 2010-09-07
ZA200202760B (en) 2003-10-29
RU2260008C2 (ru) 2005-09-10
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
GT200000158A (es) 2002-03-16
MY135058A (en) 2008-01-31
ATE422494T1 (de) 2009-02-15
PL366342A1 (en) 2005-01-24
CN100422172C (zh) 2008-10-01
HRP20020308B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-01-31
HUP0202704A3 (en) 2003-12-29
EP1228063B1 (en) 2009-02-11
AU782820B2 (en) 2005-09-01
IL148880A0 (en) 2002-09-12
DOP2000000070A (es) 2002-02-28
EE200200161A (et) 2003-08-15
NO20021520L (no) 2002-05-23
CZ304767B6 (cs) 2014-10-08
CZ20021444A3 (cs) 2002-08-14
KR100890473B1 (ko) 2009-03-26
AU1569601A (en) 2001-04-30
BG106637A (bg) 2003-02-28
KR100895572B1 (ko) 2009-04-29
WO2001023375A2 (en) 2001-04-05
AR082231A2 (es) 2012-11-21
IL193368A0 (en) 2009-02-11
MA25563A1 (fr) 2002-10-01
AR025752A1 (es) 2002-12-11
MY143580A (en) 2011-05-31
EE05258B1 (et) 2010-02-15
CN1420879A (zh) 2003-05-28
CA2385817A1 (en) 2001-04-05
IL193368A (en) 2011-05-31
KR20020038775A (ko) 2002-05-23
HRP20020308A2 (en) 2004-06-30
HUP0202704A2 (hu) 2002-12-28
NO20021520D0 (no) 2002-03-26
TW593315B (en) 2004-06-21

Similar Documents

Publication Publication Date Title
HU230223B1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them
TWI352086B (en) Trisubstituted amine compound
CN105358151B (zh) 用于治疗脊髓性肌萎缩的化合物
HU229514B1 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
HU229553B1 (en) 1,2-dihydropyridine compound, process for preparation of the same and use thereof
JP2008505907A (ja) 癌治療を目的として肝細胞増殖因子およびc−met活性を調整するキナゾリンモジュレーター
TW200823215A (en) Pyrazolopyrimidines, a process for their preparation and the use as a medicine
TW200806675A (en) Heterobicyclic thiophene compounds and methods of use
UA76726C2 (uk) Метаботропічні антагоністи рецептора глутамату, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб її одержання
CN106659706A (zh) 铂化合物、组合物及其用途
TW200800264A (en) Compounds for modulating TRPA1 function
TW201113272A (en) Novel pyrimidine-and triazine hepcidine antagonists
HUE029036T2 (en) FGF receptor (FGFR) agonist dimer compounds, methods for their preparation and their therapeutic use
CN102617548A (zh) 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
DE69909209T2 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
TW201031664A (en) Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2019535820A (ja) 選択性ブルトン型チロシンキナーゼ阻害剤及びその使用
JP7025555B2 (ja) 一過性受容体電位a1イオンチャネルの阻害
CN109790144A (zh) 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
CN109890388A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
EP2552450A1 (de) Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren
TW200927746A (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
CN109863139A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
EP4326713A1 (en) Substituted fused bicyclic compounds as parp inhibitors and the use thereof
CN112125902A (zh) 一种选择性抑制激酶化合物及其用途

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BAYER HEALTHCARE LLC, US

Free format text: FORMER OWNER(S): BAYER CORP., US; BAYER PHARMACEUTICALS CORPORATION, US

MM4A Lapse of definitive patent protection due to non-payment of fees